Mediwelcome Healthcare Management & Technology Inc. (2159) AI Stock Analysis

• Market Cap: HK$350.00M
• Dividend Yield: N/A
• Average Volume (3M): 143.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: -5.38%
• EPS Growth: 63.93%
• Country: HK
• Employees: 311
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.03
• Shares Outstanding: 280,000,000
• 10 Day Avg. Volume: 118,880
• 30 Day Avg. Volume: 143,186
• PEG Ratio: 0.04
• Price to Book (P/B): 1.31
• Price to Sales (P/S): 0.29
• P/FCF Ratio: -3.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: HK$1.00 ▼(-19.35% Downside)

The score is held down primarily by weak financial fundamentals—declining revenue, ongoing losses, and negative operating/free cash flow—along with a negative P/E that limits valuation confidence. Technicals are mixed and provide only modest support, with largely neutral momentum and the price above the 200-day average but below the 20-day average.

Positive Factors

Recurring revenue model

A subscription/licensing-based revenue mix creates recurring income and customer stickiness. Combined with structural digital-health adoption and telehealth tailwinds, this supports predictable revenue streams and long-term customer relationships even as near-term sales fluctuate.

Improving gross margin

A rising gross margin indicates early progress on cost of goods sold and unit economics. If sustained, improved margins provide operating leverage to narrow losses and support profitability once revenue stabilizes, reflecting durable operational improvements rather than short-term cost cuts.

Positive equity and moderate leverage

Positive shareholders' equity and moderate debt provide a financial cushion and flexibility to invest in product development or sales. This balance-sheet buffer reduces immediate solvency risk and supports strategic initiatives over the coming months without urgent refinancing needs.

Negative Factors

Declining revenue trend

Sustained top-line decline erodes scale, reduces pricing power, and weakens recurring revenue benefits. Over months, shrinking revenue makes it harder to leverage fixed costs, threatens customer retention economics, and increases reliance on new sales to restore growth momentum.

Negative cash flow

Consistent negative operating and free cash flows signal cash burn that limits reinvestment in R&D and commercial expansion. Over a multi-month horizon, weak cash generation forces external financing, increasing dilution or debt and constraining strategic flexibility.

Persistent operating losses

Ongoing negative EBIT and net margins indicate the business has not converted revenue into sustainable profits. Without structural revenue recovery or continued margin improvement, prolonged losses undermine the path to self-funded growth and raise questions about long-term viability.

Mediwelcome Healthcare Management & Technology Inc. Business Overview & Revenue Model

Company Description

Mediwelcome Healthcare Management & Technology Inc. (2159) is a healthcare technology company that focuses on providing innovative management solutions and advanced technology services for the healthcare sector. The company operates across various sectors, including telemedicine, electronic health records (EHR), and healthcare analytics, aiming to improve patient outcomes and streamline healthcare operations. Mediwelcome is dedicated to enhancing the efficiency of healthcare providers through its core products, which include integrated healthcare management platforms and data analytics tools designed to optimize resource utilization and patient care.

How the Company Makes Money

Mediwelcome generates revenue primarily through the sale of its healthcare management software and technology services. Key revenue streams include subscription fees from healthcare providers for access to its software solutions, licensing fees for its proprietary technology, and consulting services aimed at implementing and optimizing healthcare systems. Additionally, the company may engage in partnerships with hospitals and healthcare organizations to provide tailored solutions, which can lead to performance-based incentives or shared savings models. The ongoing demand for digital transformation in healthcare, particularly accelerated by trends such as telehealth, further contributes to Mediwelcome's earnings by expanding its customer base and increasing recurring revenue from existing clients.

Mediwelcome Healthcare Management & Technology Inc. Financial Statement Overview

Summary

Financial performance is weak: revenue has been declining sharply (2021–2024) with negative EBIT and net income margins. Gross margin improved slightly in 2024, but persistent losses, negative operating/free cash flow, and declining equity outweigh that progress.

Income Statement

The company's revenue has been declining, with a significant drop from 2021 to 2024. The EBIT and net income margins are negative, indicating operational challenges and losses. However, there is a slight improvement in gross profit margin from 2023 to 2024, suggesting some cost management progress.

Balance Sheet

The company has maintained positive stockholders' equity, though it has declined over recent years. The debt-to-equity ratio remains moderate, showing some leverage but not excessively risky. The equity ratio is decreasing, indicating lower asset financing through equity, which could pose a risk if liabilities increase.

Cash Flow

The company struggles with cash flow, with negative operating and free cash flows in recent years. The operating cash flow to net income ratio is not meaningful due to negative values, presenting challenges in cash generation. Although there was a significant capital expenditure reduction, it wasn't enough to offset cash flow deficits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	307.94M	321.56M	331.31M	323.37M	708.36M	432.29M
Gross Profit	52.10M	51.00M	29.89M	32.55M	93.60M	96.31M
EBITDA	-14.94M	-33.61M	-74.53M	-69.08M	11.32M	46.65M
Net Income	-29.16M	-45.24M	-94.10M	-89.20M	4.64M	21.04M
Balance Sheet
Total Assets	219.14M	194.09M	214.32M	317.83M	366.70M	280.08M
Cash, Cash Equivalents and Short-Term Investments	94.24M	71.66M	80.35M	154.02M	174.83M	104.89M
Total Debt	49.38M	47.73M	31.13M	26.48M	25.18M	25.43M
Total Liabilities	150.73M	120.81M	94.35M	116.97M	73.21M	109.08M
Stockholders Equity	64.23M	71.14M	116.13M	195.02M	283.11M	161.18M
Cash Flow
Free Cash Flow	10.32M	-27.10M	-77.18M	-22.75M	-24.73M	17.31M
Operating Cash Flow	10.47M	-14.05M	-75.58M	-18.46M	262.00K	31.12M
Investing Cash Flow	-9.88M	-326.00K	16.46M	-8.36M	-16.77M	-10.98M
Financing Cash Flow	11.22M	5.68M	906.00K	54.00K	92.84M	-4.79M

Mediwelcome Healthcare Management & Technology Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.24
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2159, the sentiment is Neutral. The current price of 1.24 is below the 20-day moving average (MA) of 1.33, above the 50-day MA of 1.24, and above the 200-day MA of 1.08, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 45.26 is Neutral, neither overbought nor oversold. The STOCH value of 35.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2159.

Mediwelcome Healthcare Management & Technology Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2138	56 Neutral	HK$829.65M	-4.33	-10.08%	1.72%	-3.49%	-1567.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0401	51 Neutral	HK$72.83M	-8.50	-11.91%	―	-4.50%	75.98%
9686	48 Neutral	HK$749.27M	-9.60	-20.43%	―	―	―
2159	47 Neutral	HK$350.00M	-7.85	-35.99%	―	-5.38%	63.93%
2158	45 Neutral	HK$6.16B	-63.84	-2.23%	―	-4.99%	47.18%
2251	40 Neutral	HK$1.14B	-6.15	-12.97%	―	-32.17%	-1.20%

Mediwelcome Healthcare Management & Technology Inc. Corporate Events

Mediwelcome Eyes Full Acquisition of AI-Driven Medical Tech Firm MediAI

Mediwelcome Healthcare Management & Technology Inc. has announced that a subsidiary has signed a non-binding memorandum of understanding to acquire 100% of MediAI Technology Development Limited, whose group provides AI technology solutions to global pharmaceutical and medical device companies, including AI-powered models for specialised diseases and blockchain-based tools to ensure data authenticity and security. The potential deal, which is subject to due diligence and the negotiation of a definitive agreement during a six-month exclusivity period, could become a notifiable transaction under Hong Kong listing rules and signals Mediwelcome’s strategic push into advanced AI and Web3-enabled medical technologies, potentially enhancing its capabilities and positioning in the healthcare technology market if completed.

The most recent analyst rating on (HK:2159) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Mediwelcome Healthcare Management & Technology Inc. stock, see the HK:2159 Stock Forecast page.

Mediwelcome Clarifies Auditor Resignation Amid Cost-Cutting Drive

Mediwelcome Healthcare Management & Technology Inc. has issued a supplemental announcement clarifying the circumstances around the resignation of its auditor, Moore CPA Limited, following an earlier decision to change auditors due to audit fees deemed inconsistent with the group’s budget amid efforts to cut operating costs in a tough business climate. The company explained that Moore’s resignation cited lack of agreement on audit fees, professional risk, and internal resource constraints, and clarified that the term “professional risk” was a generic reference covering standard audit engagement risks rather than any specific issue with the company, with the board reiterating that accepting Moore’s resignation is considered in the best interests of both the company and its shareholders.

The most recent analyst rating on (HK:2159) stock is a Sell with a HK$1.00 price target. To see the full list of analyst forecasts on Mediwelcome Healthcare Management & Technology Inc. stock, see the HK:2159 Stock Forecast page.

Mediwelcome Healthcare Announces Auditor Change Amid Cost Control Measures

Mediwelcome Healthcare Management & Technology Inc. announced a change in its auditor, with Moore CPA Limited resigning due to disagreements over audit fees. The company has appointed Rongcheng (Hong Kong) CPA Limited as the new auditor to maintain audit quality and implement cost control measures, which aligns with the company’s strategy to support future business development.

The most recent analyst rating on (HK:2159) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Mediwelcome Healthcare Management & Technology Inc. stock, see the HK:2159 Stock Forecast page.

Mediwelcome Announces New Hong Kong Business Location

Mediwelcome Healthcare Management & Technology Inc. has announced a change in its principal place of business in Hong Kong to a new location at World-Wide House, effective from November 18, 2025. This move is part of the company’s strategic operations, potentially impacting its business logistics and stakeholder engagement in the region.

The most recent analyst rating on (HK:2159) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Mediwelcome Healthcare Management & Technology Inc. stock, see the HK:2159 Stock Forecast page.